Climb Bio, Inc. (CLYM) Stock Score, Valuation & Financial Research

Climb Bio, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for CLYM

Climb Bio, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 10.68. These figures are a research snapshot, not a buy or sell recommendation.

What Climb Bio, Inc. does

Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Climb Bio, Inc. is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model focuses on the research and development of novel therapeutics for immune-mediated diseases, funded primarily through capital raises and equity financing while incurring significant research and development expenses.

Products and services

  • The company is developing a pipeline of therapeutic candidates, primarily budoprutug (an anti-CD19 monoclonal antibody) for immune-mediated diseases and CLYM116.

Customer types

Patients with immune-mediated diseases.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company utilizes third-party contract manufacturing organizations for the production of its clinical trial materials. Source

Business relationships and partnerships

  • ProBioGen — The company has an agreement with ProBioGen for potential manufacturing services related to budoprutug, which includes provisions for milestone payment reductions. Source

Business strengths to evaluate

  • Proprietary SC formulation of budoprutug demonstrating high bioavailability and B-cell depletion Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on the success of a limited number of clinical-stage product candidates Source

Sources: Company research source · Proprietary SC formulation of budoprutug demonstrating high bioavailability and B-cell depletion

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

CLYM financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 10.68
Market capitalization:
611.57M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -57.62M
Free cash flow:
USD -54.54M
Cash:
USD 44.11M
Total debt:
USD 1.31M
EPS:
USD -0.83

What stands out

  • Free cash flow is USD -54.54M, negative for the stored period.
  • The balance sheet shows USD 44.11M of cash versus USD 1.31M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 42.79M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for CLYM

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can CLYM fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is CLYM likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for CLYM to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of CLYM's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research CLYM

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.